Speaker Profile
Ph.D., CEO, Founder, NeoSplice Tx
Biography
Evgeny Kiner is the founder of NeoSplice Therapeutics, an AI-driven platform company unlocking disease-specific therapeutic targets that are inaccessible to traditional genomics. He was trained in RNA biology at Massachusetts Institute of Technology under Phillip Sharp, and later in systems immunology at Harvard University with Diane Mathis and Christophe Benoist, where he helped bring single-cell RNA sequencing into large-scale immune profiling efforts as part of the Immgen consortium. He is the author of a highly cited Nature Immunology study that reshaped understanding of CD4 T-cell states. Prior to NeoSplice, he was a founding scientist at Immunai, where he helped build AI-driven platforms for biological discovery. Evgeny is passionate about expanding the druggable target space and accelerating the path from data to medicines using AI.
Talk
The Gene-Level Ceiling in AI Drug Discovery
NeoSplice applies AI, isoform-resolved sequencing, single-cell resolution, and proteogenomics to uncover and validate disease-specific proteoforms as novel therapeutic targets. By integrating patient-scale validation, cell-type specificity, protein evidence, and structural modeling, we enable discovery of actionable targets for next-generation antibody and T-cellbased therapies.
AI for Emerging Therapeutics Showcase:
NeoSplice Therapeutics
NeoSplice expands the universe of druggable targets by using AI, transcriptomics, and proteomics to uncover disease-specific proteoforms inaccessible to conventional genomics, thus enabling precision therapeutics.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 AI for Emerging Therapeutics Showcase will provide a 15-30 minute time slot for selected companies to explore the transformative role of artificial intelligence in accelerating the discovery, development, and optimization of novel therapeutic modalities. From predictive algorithms for drug efficacy to real-time analysis in clinical trials, AI is revolutionizing the way we approach emerging therapies, including RNA-based treatments, gene editing, and personalized medicine. Industry leaders and experts will discuss AI-driven advancements, collaborative frameworks, and the challenges of integrating cutting-edge technologies into therapeutic innovation. Join us for an in-depth look at how AI is shaping the future of breakthrough therapeutics.
